{"id":28503,"date":"2024-10-31T09:12:03","date_gmt":"2024-10-31T08:12:03","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=28503"},"modified":"2024-10-31T09:12:03","modified_gmt":"2024-10-31T08:12:03","slug":"impilo-stanger-en-continuation-fund-pa-eur-320-miljoner","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/impilo-stanger-en-continuation-fund-pa-eur-320-miljoner\/","title":{"rendered":"Impilo st\u00e4nger en \u201dContinuation Fund\u201d p\u00e5 EUR 320 miljoner"},"content":{"rendered":"<p class=\"preamble\">Mannheimer Swartling har agerat juridisk r\u00e5dgivare \u00e5t Impilo vid etableringen av Impilo Orphan Drugs, en s.k. <em>\u201dContinuation Fund\u201d<\/em>.<\/p>\n<p>Kapitalet restes fr\u00e5n en internationell investerarbas och kommer att anv\u00e4ndas f\u00f6r att investera i Immedica f\u00f6r att m\u00f6jligg\u00f6ra Impilos och Immedicas fortsatta samarbete tillsammans med KKR, som nyligen blev j\u00e4mb\u00f6rdig \u00e4gare i Immedica tillsammans med Impilo.<\/p>\n<p>Impilo \u00e4r ett nordiskt investmentbolag som fokuserar p\u00e5 investeringar i f\u00f6retag verksamma inom l\u00e4kemedel, medicinteknik, sjukv\u00e5rdstj\u00e4nster och andra h\u00e4lsorelaterade branscher. Impilo har en v\u00e4ldiversifierad portf\u00f6lj av investeringar inom h\u00e4lsov\u00e5rd och f\u00f6rvaltar cirka 1 miljard euro i kapital fr\u00e5n ledande nordiska och internationella investerare.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mannheimer Swartling har agerat juridisk r\u00e5dgivare \u00e5t Impilo vid etableringen av Impilo Orphan Drugs, en s.k. \u201dContinuation Fund\u201d. Kapitalet restes fr\u00e5n en internationell investerarbas och\u2026<\/p>\n","protected":false},"author":16,"featured_media":28504,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-28503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-eu-och-konkurrensratt","business-group-fonder-och-investeringar","business-group-foretagsoverlatelser"],"acf":[],"lang":"sv","translations":{"sv":28503,"en":28508},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/28503"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=28503"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/28503\/revisions"}],"predecessor-version":[{"id":28507,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/28503\/revisions\/28507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/28504"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=28503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=28503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=28503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}